Patent application number | Description | Published |
20080305959 | Laser microdissection and microarray analysis of breast tumors reveal estrogen receptor related genes and pathways - About 70% to 80% of breast cancers express estrogen receptor-α (ERα), and estrogens play important roles in the development and growth of hormone-dependent tumors. Together with lymph node metastasis, tumor size and histological grade, ER status is considered one of the prognostic factors in breast cancer, and an indicator for hormonal treatment. 147 genes and 112 genes with significant P-value and having significant differential expression between ER+ and ER− tumors were identified from the LCM data set and bulk tissue data set, respectively. 61 genes were found to be common in both data sets, while 85 genes were unique to the LCM data set and 51 genes were present only in the bulk tumor data set. Pathway analysis with the 85 genes using Gene Ontology suggested that genes involved in endocytosis, ceramide generation, Ras/ERK/Ark cascade, and JAT-STAT pathway may play roles related to ER. The gene profiling with LCM-captured tumor cells provides a unique approach to characterize and study epithelial tumor cells and to gain an insight into signaling pathways associated with ER. | 12-11-2008 |
20090221445 | Cancer Diagnostic Panel - A method of diagnosing cancer by identifying differential modulation of each gene (relative to the expression of the same genes in a normal population) in a combination of genes selected from two groups of genes. | 09-03-2009 |
20100009861 | BREAST CANCER PROGNOSTICS - A method of providing a prognosis of breast cancer is conducted by analyzing the expression of a group of genes. Gene expression profiles in a variety of medium such as microarrays are included as are kits that contain them. | 01-14-2010 |
20110009288 | METHODS AND REAGENTS FOR THE EARLY DETECTION OF MELANOMA - An assay for identifying early stage malignant melanocyte in biopsy tissues is provided by determining whether differential expression of a particular gene indicative of melanoma exceed a cut-off value. | 01-13-2011 |
Patent application number | Description | Published |
20090155805 | COPY NUMBER ALTERATIONS THAT PREDICT METASTATIC CAPABILITY OF HUMAN BREAST CANCER - Disclosed in this specification is a method of defining chromosome regions of prognostic value by summarizing the significance of all SNPs (single nucleotide polymorphism) in a predetermined section of a chromosome to define chromosome regions of prognostic value. Based on the SNPs in specified genes, a more accurate prognosis for breast cancer may be provided. | 06-18-2009 |
20090192045 | MOLECULAR STAGING OF STAGE II AND III COLON CANCER AND PROGNOSIS - Kits and articles include reagents for conducting a seven gene assay to stage colon cancer as Stage II or Stage III colon cancer. | 07-30-2009 |
20100021886 | Methods and Materials for Identifying the Origin of a Carcinoma of Unknown Primary Origin - The present invention provides a method of identifying origin of a metastasis of unknown origin by obtaining a sample containing metastatic cells; measuring Biomarkers associated with at least two different carcinomas; combining the data from the Biomarkers into a linear discrimination analysis where the linear discrimination analysis normalizes the Biomarkers against a reference; and imposes a cut-off which optimizes sensitivity and specificity of each Biomarker, weights the prevalence of the carcinomas and selects a tissue of origin determining origin based on highest probability determined by the linear discrimination analysis or determining that the carcinoma is not derived from a particular set of carcinomas; and optionally measuring Biomarkers specific for one or more additional different carcinoma, and repeating the steps for additional Biomarkers. | 01-28-2010 |
20100041051 | Prostate Cancer Methylation Assay - An assay for diagnosing or prognosticating prostate cancer incorporates the detection of hypermethylation of SEQ ID NO 1, SEQ ID NO 3, and SEQ ID NO 2 genes and may be incorporated into a nomogram. | 02-18-2010 |
20110166030 | Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells - A method for predicting with high specificity from RTPCR detected markers if a patent is likely to respond to docetaxel treatment is disclosed. RTPCR detects the presence of absence of certain mutations due to fusion events. Together, with other protein markers, additional stratification is possible to identify patents suited for docetaxel therapy as opposed to for alternative treatments. | 07-07-2011 |
20110275079 | DIAGNOSTIC BIOMARKERS OF DIABETES - Methods are disclosed for the identification of gene sets that are differentially expressed in PBMCs of patients diagnosed with a pre-diabetic disease state and overt type II diabetes. 3 gene and 10 gene signatures are shown to accurately predict a diabetic disease state in a patient. The application also described kits for the rapid diagnosis of diabetic disease states in patients at a point of care facility. | 11-10-2011 |
20130059755 | Gene Based Prediction of PSA Recurrence for Clinically Localized Prostate Cancer Patients - Disclosed are methods, devices and kits for determining the likelihood of recurrence of prostate cancer using the expression levels of preferably three-gene classifier. The methods, devices and kits can be used independent of many nomograms currently in use or to improve the overall performance of such nomograms. | 03-07-2013 |
20130217011 | DIAGNOSTIC BIOMARKERS OF DIABETES - Methods are disclosed for the identification of gene sets that are differentially expressed in PBMCs of patients diagnosed with a pre-diabetic disease state and overt type II diabetes. 3 gene and 10 gene signatures are shown to accurately predict a diabetic disease state in a patient. The application also described kits for the rapid diagnosis of diabetic disease states in patients at a point of care facility. | 08-22-2013 |
20140303028 | GENOMIC DIAGNOSTICS USING CIRCULATING ENDOTHELIAL CELLS - Circulating Endothelial Cells are isolated from patient blood and gene expression of the cells is analyzed to assess a medical condition or the tissue of origin of the cell. Kits for conducting the method are also provided. | 10-09-2014 |